Core Viewpoint - Ypsomed Holding AG has completed the sale of its diabetes care business to TecMed AG for 420 million Swiss francs (approximately 3.7 billion RMB), marking a strategic shift towards focusing on subcutaneous self-injection solutions and expanding global production capacity [2][4][5] Group 1: Transaction Details - The sale process for Ypsomed's diabetes care business began in November 2024 and was awarded to TecMed AG, controlled by the family of Ypsomed's founder Willy Michel [4] - The transaction includes the complete transfer of the mylife Loop system, related R&D and marketing teams totaling around 200 employees, and some patch pump technology reserves [4][5] Group 2: Strategic Focus of Ypsomed - Ypsomed's CEO Simon Michel stated that this transaction represents a strategic watershed moment, allowing the company to focus solely on self-injection solutions and deepen collaborations with global pharmaceutical clients [5][10] - The funds from the transaction will be used to support Ypsomed's global manufacturing expansion plans, aiming to create a multi-center production network compliant with global standards [10][11] Group 3: TecMed's Development Plans - TecMed aims to integrate the mylife pump products with its existing patch pump development path to create a cohesive infusion platform [5][10] - The company is exploring partnerships with Abbott to integrate future glucose/ketone dual sensors with its pump systems, advancing a "monitoring-infusion-control" closed-loop design [10][12] Group 4: Market Positioning and Challenges - Following the acquisition, TecMed will advance both the tubular and patch pump technologies, positioning itself among the leading players in the global diabetes infusion device market [12][15] - TecMed faces challenges common to medical device companies, including engineering complexity, market inertia, and reimbursement access, which could impact its commercialization efforts [15][16]